目的：由于皮肤切除性黑素瘤（SKCM）患者对免疫疗法反应存在差异，迫切需要准确的生物标志物来预测免疫疗法的疗效。方法：本研究采用单变量回归模型和生存分析，研究钙电压门控通道亚单位α1C（CACNA1C）突变状态与接受免疫疗法的SKCM患者的免疫疗效之间的关联。还进行了突变谱、免疫原性、肿瘤微环境和通路富集分析。结果：CACNA1C突变组预后较好，免疫原性更高，内皮细胞浸润较低，抗肿瘤免疫反应通路显著富集，并明显抑制了促肿瘤通路。结论：CACNA1C突变状态有望成为预测黑色素瘤免疫疗法效果的生物标志物。

Aims: There is an urgent need for appropriate biomarkers that can precisely and reliably predict immunotherapy efficacy, as immunotherapy responses can differ in skin cutaneous melanoma (SKCM) patients. Methods: In this study, univariate regression models and survival analysis were used to examine the link between calcium voltage-gated channel subunit alpha 1C (CACNA1C) mutation status and immunotherapy outcome in SKCM patients receiving immunotherapy. Mutational landscape, immunogenicity, tumor microenvironment and pathway-enrichment analyses were also performed. Results: The CACNA1C mutation group had a better prognosis, higher immunogenicity, lower endothelial cell infiltration, significant enrichment of antitumor immune response pathways and significant downregulation of protumor pathways. Conclusion: CACNA1C mutation status is anticipated to be a biomarker for predicting melanoma immunotherapy effectiveness.